. 2022; 19(2): 0-0 | |||
Ondansetron versus metoclopramide for the management of hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trialsEbraheem Albazee1, Lina Almahmoud1, FIRAS AL-RSHOUD2, Dima Sallam1, Wardah Albzea3, Rawan Alenezi4, Saeed Baradwan5, Ahmed Abu-Zaid61Faculty of Medicine, The Hashemite University, Zarqa, Jordan2Department of Obstetrics and Gynaecology, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan 3Faculty of Medicine, Alexandria University, Alexandria, Egypt 4Faculty of Medicine, University of Jordan, Amman, Jordan 5Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia 6Department Pharmacology, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed to examine the efficacy of ondansetron (intervention) versus metoclopramide (control) in managing pregnant women with hyperemesis gravidarum (HG). Ebraheem Albazee, Lina Almahmoud, FIRAS AL-RSHOUD, Dima Sallam, Wardah Albzea, Rawan Alenezi, Saeed Baradwan, Ahmed Abu-Zaid. Ondansetron versus metoclopramide for the management of hyperemesis gravidarum: A systematic review and meta-analysis of randomized controlled trials. . 2022; 19(2): 0-0 Corresponding Author: Ahmed Abu-Zaid, United States of America |
|